Antidepressants & Pregnancy: Risks of Stopping & Impact on Birth Outcomes
New research published this month indicates that discontinuing antidepressant medication during pregnancy nearly doubles the risk of a mental health emergency for the expectant mother, prompting renewed debate among healthcare professionals regarding the optimal management of depression during this period.
The findings, reported by The New York Times on February 11, 2026, challenge previous assumptions about the risks of continued antidepressant leverage versus the potential consequences of cessation. While concerns about potential birth defects associated with selective serotonin reuptake inhibitors (SSRIs) have long been a primary consideration for pregnant patients and their doctors, the new data suggest that the risks of untreated or destabilized depression may be significantly higher.
The decision to use antidepressants during pregnancy has always been a complex balancing act, according to experts at the Mayo Clinic. A 2023 assessment highlighted that while all medications carry some risk during pregnancy, the overall risk of birth defects and other problems for babies born to mothers taking antidepressants is generally low. However, the potential for untreated depression to lead to premature birth, low birth weight, and difficulties with prenatal care and maternal self-care remains a serious concern.
“It’s crucial to feel good during pregnancy,” stated Diana Isaacs, PharmD, an endocrine clinical pharmacist at Cleveland Clinic, in an April 2025 report. “When you do, you’re more likely to take better care of yourself, and that’s always the best thing for healthy fetal development.” The American College of Obstetricians and Gynecologists (ACOG) estimates that approximately one in ten women experience depression during pregnancy, underscoring the prevalence of the condition and the need for effective treatment strategies.
The potential risks associated with specific antidepressants are also under scrutiny. The Cleveland Clinic has identified paroxetine as a less favorable option for pregnant women due to potential side effects. Healthcare teams are increasingly focused on minimizing fetal exposure to medication by prescribing a single antidepressant at the lowest effective dose, particularly during the first trimester, according to guidance from Johns Hopkins Medicine.
Beyond medication, talk therapy remains a viable option for managing depression during pregnancy. However, the recent research suggests that for many women, continuing antidepressant treatment may be the safer course. The implications of these findings are still being evaluated by medical organizations, and further research is planned to determine the long-term effects of both continuing and discontinuing antidepressant medication during pregnancy.